New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:34 EDTNSTGNanoString launches nCounter PanCancer Pathways Panel
NanoString Technologies announced the launch of the nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a way for translational researchers to investigate cancer biology across all major cancer pathways. A growing body of research has demonstrated that a pathway-based approach to the analysis of gene expression provides a framework for understanding the changes between the biology of different cancers and cancer subtypes. From a single tube, the PanCancer Pathways Panel simultaneously analyzes of all of the key cancer pathways: PI3K, STAT, MAPK, TGF, Notch, Hedgehog, Wnt, Apoptosis, Cell Cycle, RAS, Chromatin Modification, Transcriptional Regulation and DNA Damage Control. Processing samples on the nCounter Analysis System takes just 15 minutes of hands-on time and generates reproducible data, representing a solution for studying cancer.
News For NSTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
16:48 EDTNSTGNanoString raises FY15 revenue view to $60M-$63M from $58M-$61M
Consensus is for FY15 revenue $59.15M. Sees FY15 gross margin in the range of 53% to 55%, unchanged; operating expenses in the range of $77M-$81M, unchanged; and operating loss in the range of $41M-$47M, compared to the previous range of $43M-$49M.
16:46 EDTNSTGNanoString reports Q2 EPS (66c), consensus (57c)
Reports Q2 revenue $13.1M, consensus $12.80M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use